BIL06v is a vaccine therapy for cancer which recruits the individual’s own immune system to generate antibodies that target specifically cancer cells that express nfP2X7.
BIL06v is intended for use as therapy against the broad range of solid and haematological tumours seen to express nfP2X7, and has potential to be used both prophylactically and for treatment of established cancers. The vaccine is a peptide antigen conjugated to a protein that stimulates the immune system to generate antibodies that bind to nfP2X7 leading to cell death.
Vaccines are a promising approach to cancer treatment, as they are cheaper to produce than other biological products such as antibodies, lower in dosage and thus have less toxicity concerns, and the treatment administration regime is easier and less frequent than infusions. Global revenues for cancer vaccines market are forecast to grow at a compound annual growth rate (CAGR) of 16.93%, from $2.5 billion in 2015 to $7.5 billion in 2022.
A major challenge in vaccine oncology is to develop a therapy that can drive the patients’ immune system consistently against a target on the cancer cell which is not protected by immune tolerance for the bodies’ own tissues. BIL06 v has been shown to successfully and consistently break immune tolerance, and the immune response generated by BIL06v has been shown to reduce tumour growth and metastasis in vivo.
A Phase 1 trial is approved by regulators scheduled to begin recruitment in mid 2018.